← Back to Search

[18F]-Fluorodeoxyglucose for Tumors

Phase 3
Waitlist Available
Led By Daniel P Levin, BSc,MD,FRCPC
Research Sponsored by University of Manitoba
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up three years
Awards & highlights

Study Summary

This clinical trial is being conducted to study the use of a radioactive glucose tracer as an imaging test [Positron Emission Tomography (PET)scan] in adults who have or are suspected of having cancer and in another group of adults to assess for neurologic conditions.

Eligible Conditions
  • Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~three years
This trial's timeline: 3 weeks for screening, Varies for treatment, and three years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To confirm the diagnostic effectiveness of 18F-Fluorodeoxyglucose(FDG) as compared to the gold standard of histopathological diagnosis.

Side effects data

From 2015 Phase 2 trial • 59 Patients • NCT01146054
29%
Anemia
29%
Lymphocyte count decreased
27%
Anorexia
27%
Fatigue
24%
Abdominal Pain
12%
Nausea
10%
Platelet Count Decreased
8%
Dyspepsia
6%
Constipation
2%
Duodenal hemorrhage
2%
Duodenal Ulcer
2%
Dehydration
2%
Sepsis
2%
Duodenal Fistula
100%
80%
60%
40%
20%
0%
Study treatment Arm
SBRT and Gemzar

Trial Design

1Treatment groups
Experimental Treatment
Group I: [18F]-FluorodeoxyglucoseExperimental Treatment1 Intervention
Scanning Procedure: Non-diagnostic Computed Tomography (CT) scan followed by a Diagnostic Positron Emission Tomography (PET) scan.

Find a Location

Who is running the clinical trial?

Winnipeg Regional Health AuthorityOTHER
8 Previous Clinical Trials
940 Total Patients Enrolled
University of ManitobaLead Sponsor
595 Previous Clinical Trials
198,526 Total Patients Enrolled
Daniel P Levin, BSc,MD,FRCPCPrincipal InvestigatorWinnipeg Regional Health Authority

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology
2010. "18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01180751.
All > Flu
~68 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top